drug
as of 2026-07-01Metformin
metformin
MeSH D008687
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Central South University
22 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
22
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
NCT07342764Phase 4Not Yet Recruiting
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
NCT07045142Phase 3Recruiting
Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
NCT07001878Phase 4Recruiting
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
NCT03271866—Unknown
Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
NCT03708549Phase 4Unknown
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
NCT05663749Phase 4Completed
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
NCT04865835Phase 1Completed
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
NCT02796144Phase 4Terminated
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
NCT02167620Phase 4Completed
The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine
NCT01654640Phase 4Terminated
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
NCT00806234Phase 4Completed
Effects of Metformin and Fish Oil on Treatment With Clozapine
NCT02140788Phase 4Terminated
Metformin for Treatment of Antipsychotic-induced Dyslipidemia
NCT01778244Phase 4Completed
Metformin for the Prevention of the Metabolic Side-effects of Zyprexa
NCT00682448Phase 4Completed
Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
NCT06326840—Completed
Metformin for Weight Loss in Schizophrenia
NCT01177709—Terminated
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
NCT00816907Phase 4Completed
Cardio Risk of Acute Schizophrenia Olanzapine Duke
NCT00672464Phase 4Withdrawn
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
NCT00802100Phase 4Completed
Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients
NCT01300637—Unknown
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
NCT00401973Phase 3Completed
An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00391261Phase 4Completed
KOLs & investigators
12
Christoph U. Correll, MDKOL score 96
Renrong Wu, ProfKOL score 10
Margaret K Hahn, PhD, MDKOL score 10
Philip G Tibbo, MDKOL score 10
Robert C. Smith, MD, PhDKOL score 9
Jeffrey A. Lieberman, MDKOL score 9
T. Scott Stroup, MD, MPHKOL score 5
Renrong Wu, M.D., Ph.D.KOL score 5
Chun-Hsin Chen, MDKOL score 5
Jeffrey A Lieberman, M.D.KOL score 5
Mong-Liang Lu, MDKOL score 5
Joseph P. McEvoy, MDKOL score 4
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
trial
indication
KOL
Christoph U. Correll, MD
personKOL score 96
Renrong Wu, Prof
personKOL score 10
Margaret K Hahn, PhD, MD
personKOL score 10
Philip G Tibbo, MD
personKOL score 10